Iterum Therapeutics plc (ITRMF) is a commercial-stage Irish pharma entity with a single approved product, ORLYNVAH (oral sulopenem), launched in the U.S. following FDA approval in October 2024. Under a liquidation lens as of September 30, 2025, equity recovery is negative and deeply so. Total assets are $32.5M against total liabilities of $39.9M, producing book equity of negative $7.4M. Applying standard liquidation haircuts worsens this materially: cash of $11.0M recovers at 100% ($11.0M); AR of $0.4M at 90-95% (~$0.4M); inventory of $1.1M at 60% (~$0.7M); PP&E net $18K at 50-70% (negligible); intangibles (capitalized ORLYNVAH NDA, gross $20.0M, net $18.7M) recover at 0% under liquidation convention given no established royalty stream or proven buyer market for this early-commercial asset. Prepaid and other current assets of $1.1M recover partially (~$0.5M). Gross liquidation asset pool is approximately $12.6M against face-value liabilities of $39.9M, implying an estimated liquidation deficit to equity of approximately negative $27M, far exceeding the negative book equity figure. The largest liability is $20.0M of long-term debt (Pfizer promissory note, maturing year four per maturity schedule) plus $5.2M of accrued liabilities and $6.4M total current liabilities. The RLN structure (royalty-linked notes issued by Iterum Bermuda, obligating 15% of U.S. net revenues through 2045, with a maximum return of $160/RLN) represents a contingent off-balance-sheet encumbrance on future ORLYNVAH revenues that is not reflected at face value on the current balance sheet but would be a first claim on commercialization proceeds in any going-concern scenario, further impairing equity recovery. Cash burn is severe: operating cash outflow was $15.3M for the nine months ended September 30, 2025, and the period opened with approximately $24.2M in cash (implied from ending $11.0M plus net burn). The company raised $16.9M in equity proceeds during the period but also repaid $14.7M of long-term debt. Nasdaq minimum bid price deficiency notice received August 25, 2025, with a February 23, 2026 compliance deadline; shareholder votes to authorize additional share issuances failed at the September 2025 AGM, constraining future equity capital access. The filing does not separately tag the RLN principal obligation or the RLN maximum return exposure in XBRL; these are disclosed in MD&A and risk factors only. The new Commercial Manufacturing and Supply Agreement with ACS Dobfar (July 2025) and the Product Commercialization Agreement with EVERSANA (June 2025, prior period) add undisclosed production and commercialization cost commitments that do not extinguish on windup and are not separately XBRL-tagged.
▼ Community Notes